The Clinical Trials Research Unit at the University of Leeds has produced a series of webinars for researchers and clinicians about the UK Myeloma Research Alliance (UKMRA)-Myeloma UK-Concept and Access Research Programme (CARP) and how it supports the development of early phase myeloma clinical trials in the UK.
Early diagnosis of myeloma relies on primary care clinicians being able to accurately suspect, test and refer patients with suspected myeloma. It is important that GPs are able to distinguish those patients that require urgent investigation in secondary care versus those that likely have lower risk MGUS and so can be monitored in primary care or via discussion…
In collaboration with colleagues from the UKMF, Myeloma UK have developed a set of slides and a corresponding poster that are available to download and use in a Grand Round event.
We have co-partnered education events for GPs with a number of Clinical Commissioning Groups across the UK.
Please get in touch if you can direct us to the relevant person in your local CCG or if you would be interested in hosting a GP education event at your hospital. Email firstname.lastname@example.org
We have collaborated with Macmillan to produce a Myeloma 10 top tips factsheet to support myeloma diagnosis by raising GP awareness. This includes guidance on when to suspect myeloma and which blood tests should be requested. The factsheet has been reviewed by expert haematologists and Macmillan GP Advisors to ensure the content is accurate from the perspective of both primary and secondary care clinicians.
Early diagnosis for myeloma patients is associated with improved overall survival. The one year survival rate for patients diagnosed via GP referral is significantly higher than those diagnosed following emergency admission (88% vs 62%). Fundamental to timely diagnosis of rarer cancers such as myeloma is increased GP awareness.
HM-PRO: A Novel Patient-Reported Outcome Measure in Haematological Malignancy for Use in Clinical Practice
The haematological malignancies patient report outcomes (HM-PRO) measure has been developed to support patients and their clinicians in discussing, addressing and better recording quality of life issues that matter patients.
The Myeloma Diagnosis Pathway is an easy to follow, quick reference tool to help GPs and other healthcare professionals recognise the signs and symptoms of myeloma. It provides information on which tests and investigations should be conducted before referral to a haematologist. It has been designed by Myeloma UK and reviewed by a working group…
Common Terminology Criteria for Adverse Events (CTCAE) is widely accepted as the standard classification and severity grading scale for adverse events in cancer therapy, clinical trials and other oncology settings. Version 5.0 is the most updated document (November 27, 2017)
This document explains the aims of the Myeloma UK Nursing Best Practice Guides and how they should be used to enhance knowledge and inform nursing practice thus enabling nurses to deliver the highest possible treatment, care and support to myeloma patients and their families.